Winton Group’s ALX Oncology ALXO Stock Holding History

Winton Group’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-7,058	Closed	-$521K	–	1007
2021 Q3	$521K	Buy	7,058 +1,821	+35%	+$121K	0.03%	839
2021 Q2	$286K	Buy	+5,237	New	+$313K	0.02%	1203

Other funds holding ALXO

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Winton Group's ALXO Position: Q4 2021 in Review

Winton Group sold out of ALX Oncology (ALXO) in Q4 2021, closing a stake of 7,058 shares — an estimated $521K sold.

Winton Group first reported a position in ALXO in Q2 2021 and held it in 2 quarters. The position peaked at $521K in Q3 2021. 108 funds tracked by Wall St. Rank hold ALXO as of Q4 2021.

Winton Group reported no remaining ALX Oncology position as of Q4 2021 after selling out during the quarter.
Winton Group sold 7,058 ALX Oncology shares in Q4 2021, an estimated $521K.
Winton Group first reported a position in ALX Oncology in Q2 2021 and held it in 2 quarters.
Winton Group's ALX Oncology position peaked at $521K in Q3 2021.
108 funds tracked by Wall St. Rank held ALX Oncology as of Q4 2021.

Based on Winton Group's 13F filing for Q4 2021, filed 10 Feb 2022.